• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Insights into the antigenic advancement of influenza A(H3N2) viruses, 2011-2018

tetano

Editor, Senior Moderator
Sci Rep. 2019 Feb 25;9(1):2676. doi: 10.1038/s41598-019-39276-1.
[h=1]Insights into the antigenic advancement of influenza A(H3N2) viruses, 2011-2018.[/h] Jorquera PA[SUP]1,[/SUP][SUP]2[/SUP], Mishin VP[SUP]1[/SUP], Chesnokov A[SUP]1[/SUP], Nguyen HT[SUP]1,[/SUP][SUP]3[/SUP], Mann B[SUP]1,[/SUP][SUP]3[/SUP], Garten R[SUP]1[/SUP], Barnes J[SUP]1[/SUP], Hodges E[SUP]1,[/SUP][SUP]2[/SUP], De La Cruz J[SUP]1,[/SUP][SUP]3[/SUP], Xu X[SUP]1[/SUP], Katz J[SUP]1[/SUP], Wentworth DE[SUP]1[/SUP], Gubareva LV[SUP]4[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Influenza A(H3N2) viruses evade human immunity primarily by acquiring antigenic changes in the haemagglutinin (HA). HA receptor-binding features of contemporary A(H3N2) viruses hinder traditional antigenic characterization using haemagglutination inhibition and promote selection of HA mutants. Thus, alternative approaches are needed to reliably assess antigenic relatedness between circulating viruses and vaccines. We developed a high content imaging-based neutralization test (HINT) to reduce antigenic mischaracterization resulting from virus adaptation to cell culture. Ferret reference antisera were raised using clinical specimens containing viruses representing recent vaccine strains. Analysis of viruses circulating during 2011-2018 showed that gain of an N158-linked glycosylation in HA was a molecular determinant of antigenic distancing between A/Hong Kong/4801/2014-like (clade 3C.2a) and A/Texas/50/2012-like viruses (clade 3C.1), while multiple evolutionary HA F193S substitution were linked to antigenic distancing from A/Switzerland/97152963/2013-like (clade 3C.3a) and further antigenic distancing from A/Texas/50/2012-like viruses. Additionally, a few viruses carrying HA T135K and/or I192T showed reduced neutralization by A/Hong Kong/4801/2014-like antiserum. Notably, this technique elucidated the antigenic characteristics of clinical specimens, enabling direct characterization of viruses produced in vivo, and eliminating in vitro culture, which rapidly alters the genotype/phenotype. HINT is a valuable new antigenic analysis tool for vaccine strain selection.


PMID: 30804469 DOI: 10.1038/s41598-019-39276-1
 
Back
Top Bottom